Zhenchang Sun

First Affiliated Hospital of Zhengzhou University — China

Medicine · Health Sciences

16h-index683citations45works6.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(24), Immune Cell Function and Interaction(11), Viral-associated cancers and disorders(7), Chronic Lymphocytic Leukemia Research(6), CAR-T cell therapy research(5)

Publications45 total

ABO Blood Group and the Risk and Prognosis of Diffuse Large B-Cell Lymphoma
Cancer Management and Research·2025Open Access
Butyrate-producing <i>Faecalibacterium prausnitzii</i> suppresses natural killer/T-cell lymphoma by dampening the JAK-STAT pathway
Gut·2024· 31 citedOpen Access
Strikingly Reduced Toxicities of Fotemustine-Based Chemotherapeutics Than High-Dose Methotrexate-Containing Regimens with Comparable Efficacy
Blood·2024· 1 citedOpen Access
Outcomes and Prognostic Factors of the Alternative Regimens for Angioimmunoblastic T Cell Lymphoma: A Retrospective Study
Blood·2024
Retraction Note: TIPE2 suppresses progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/β-catenin pathway
Journal of Translational Medicine·2024Open Access
Decitabine combined with <scp>RDHAP</scp> regimen in relapsed/refractory diffuse large B cell lymphoma
Cancer Medicine·2023· 10 citedOpen Access
Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma
Leukemia & lymphoma/Leukemia and lymphoma·2023· 1 cited
A Phase I/II Study of Orelabrutinib Combined with Anti-Programmed Cell Death Protein-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)
Blood·2022· 4 cited
Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
Clinical Cancer Research·2022· 105 citedOpen Access
CD5-positive marginal zone lymphoma: Clinicopathological features and survival outcomes
Leukemia Research·2022· 9 cited
Analysis of the Tumor Microenvironment By Quantitative Immunohistochemistry Reveals Novel Predictors in Classic Hodgkin Lymphoma Treated with Anti-PD1 Therapy
Blood·2021
Anti-PD-1-Antibody (Tislelizumab) Combined with Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory/Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial
Blood·2021· 2 cited
The Impact of the Immunophenotyping Characteristics of Patients' Peripheral Blood on the Manufacturing and Clinical Outcome of CD7-Targeted Chimeric Antigen Receptor T Cells
Blood·2021· 4 cited
CD5-Positive Marginal Zone Lymphoma: Clinicopathological Features And Survival Outcomes
Research Square (Research Square)·2021Open Access
Characteristics and Clinical Implications of the Nasal Microbiota in Extranodal NK/T-Cell Lymphoma, Nasal Type
Frontiers in Cellular and Infection Microbiology·2021· 6 citedOpen Access
Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure
Frontiers in Oncology·2021· 17 citedOpen Access
Minimal change glomerulopathy after unrelated umbilical cord blood transplantation for the treatment of children：case report
2021Open Access
Activating NOTCH1 Mutations Alter T-ALL Chemosensitivity By PREX2-AKT Pathway
Blood·2020· 2 cited
&lt;p&gt;Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases&lt;/p&gt;
OncoTargets and Therapy·2020· 16 citedOpen Access
A Phase I Clinical Trial of Chimeric Antigen Receptor-Modified T Cells in Patients with Relapsed and Refractory Lymphoma
Immunotherapy·2020· 29 cited
page 1 of 3Next →

Frequent Co-authors

Xiaorui Fu(34), Zhaoming Li(22), Mingzhi Zhang(21), Ling Li(20), Yu Chang(18), Feifei Nan(17), Xinhua Wang(17), Jiaqin Yan(17), Mingzhi Zhang(16), Xiaolong Wu(15), Xudong Zhang(13), Zhi‐Yuan Zhou(12), Lei Zhang(11), Jingjing Wu(11), Lei Zhang(11), Linan Zhu(8), Xiaoyan Feng(7), Xin Li(7), Hui Yu(6), Xu Dong Zhang(6)